Intracerebral hemorrhage (ICH) is the most devastating subtype of stroke with high mortality rates, and profound morbidity and disability. The mechanisms leading to brain damage caused by ICH are multifaceted and poorly understood. There is no FDA approved treatment for ICH. Recent studies and our preliminary work indicate that astrocytes, cells known to have a uniquely dense network of mitochondria (Mt), secrete intact Mt, which upon entering adjacent neurons or microglia could help them resist injury and promote restorative function when exposed to the damage effects of intracerebral blood products. While the biology of Mt transfer is seen as homeostatic, the mechanisms behind their beneficial effect is unclear. One of the unique functions of Mt is to produce, from its own genome, a small potent bioactive secretory peptide, humanin (HN; encoded in the Mt DNA 16S ribosomal RNA region), which acts through a specific surface receptor present in the brain, including on neurons and microglia. HN is implicated in Mt-associated longevity and has cytoprotective activities. However, the mechanism behind these beneficial effects of HN in cerebrovascular diseases and its clinical relevance remains unclear. Our extensive preliminary results demonstrate: (1) a robust Mt transfer from astrocytes to neurons or to microglia and that the transfer confers cytoptotection in neurons and a ?healing? phenotype in microglia under ICH-like conditions. (2) ICH-mediated injury in mice results in a profound loss of HN in the ICH-affected hemisphere and treatment with recombinant HN (rHN) significantly reduced neurological deficits produced by ICH. (3) HN or astrocytic Mt-transfer into neurons leads to (a) STAT3/MnSOD upregulation and reduction of oxidative damage to neurons, and (b) PPAR? upregulation in microglia and a ?healing? phenotype, including increased phagocytic capacity. Therefore, we hypothesize that Mt-derived HN, released or transferred within the intact Mt secreted from astrocytes (or injected as recombinant HN, rHN) can reduce ICH-mediated damage (1) by increasing neuronal resistance to oxidative damage (through upregulating Mt anti-oxidative Mn-SOD) and by supporting neural plasticity; and (2) by securing ?healing? (phagocytic/anti-oxidative/anti-inflammatory/trophic) phenotype of microglia, through transcription factor PPAR?.
Our specific aims are: (1) To establish (in vitro) the cellular mechanisms by which astrocytic HN and Mt transfer (A) attenuates injury to neurons and (B) promotes the ?healing? phenotype to microglia under conditions simulating ICH. (2) To determine (in vivo) the translational value and mechanism by which Mt/HN mediates protection from damage imposed by ICH. (3) To establish age/sex-related differences in Mt transfer, and HN expression by using aged male and female mice, and the therapeutic effect of HN in ICH.
Intracerebral hemorrhage (ICH), the most devastating type of stroke, is without effective treatments and is therefore a condition that needs fundamental studies on mechanisms of damage and therapeutic targets that could be used to alleviate injury caused by ICH. Astrocytes normally act to support neuronal function and have the capacity to secrete intact mitochondria (Mt), which upon entering the adjacent neurons or microglia can augment their function and help them resist injury and promote repair. Here, we propose that the Mt-derived peptide humanin (HN) (synthetized from MtDNA), released or transferred within the intact Mt from astrocytes can reduce ICH-mediated damage (1) by increasing neuronal resistance to oxidative damage through upregulating Mt anti-oxidative Mn-SOD and by supporting neural plasticity; and (2) by promoting ?healing? (phagocytic/anti-oxidative/anti-inflammatory/trophic) phenotype of microglia, through the transcription factor PPAR?. Using cell culture systems and animal models of ICH, we will evaluate the mechanisms underlying the protective effect of Mt transfer, and how responses of neurons and microglia to HN (including when injected as recombinant HN) can be translated into a treatment for ICH in young, as well as aged male and female rodents.
